AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [8-K] Keros Therapeutics, Inc. Reports Material Event

[8-K] Keros Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock KROS logo
Keros Therapeutics, Inc.

NASDAQ:KROS

KROS Rankings

#3100 Ranked by Market Cap
N/A Ranked by Dividends

KROS Latest News

Aug 28, 2025
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Aug 21, 2025
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
Aug 20, 2025
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
Aug 6, 2025
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Aug 6, 2025
Keros Therapeutics Reports Second Quarter 2025 Financial Results

KROS Latest SEC Filings

Aug 28, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Aug 21, 2025
[SCHEDULE 13D/A] Keros Therapeutics, Inc. SEC Filing
Aug 20, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Aug 15, 2025
[Form 3] Keros Therapeutics, Inc. Initial Statement of Beneficial Ownership
Aug 15, 2025
[Form 3] Keros Therapeutics, Inc. Initial Statement of Beneficial Ownership

KROS Stock Data

617.76M
38.56M
2.5%
100.64%
11.92%
Biotechnology
Pharmaceutical Preparations
United States
LEXINGTON